| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
President and CEO | President and CEO | Director
2 companies
Jacob Chacko is President and CEO at ORIC and has filed Form 4s across 2 companies. Jacob Chacko's net worth is not public. Form 4 filings only show shares in the companies where this person is an insider; those holdings are worth an estimated $5.6M at current prices.
Historically, Jacob Chacko's trades have earned a strong insider score of 77/100 across 41 rated trades. Over a 12-month horizon, 77.5% of those trades were profitable, with an average 12-month return of +45.0%.
The biggest single holding is ORIC (~$5.6M) as President and CEO. Net of sales, the ORIC filings show accumulation of 291,815 shares.
Jacob Chacko has 39 Form 4 filings on record from April 2020 to June 2026, across 2 companies: Director at 4D Molecular Therapeutics (FDMT), 2021–2026; President and CEO at Oric Pharmaceuticals (ORIC), 2020–2026.
The 72 reported transactions were 36 open-market sales, 21 option or other derivative awards, 6 open-market purchases and 5 option exercises, plus smaller numbers of other types.
Counted by filing, the open-market trades come to 2 purchases worth about $3.0M and 22 sales worth about $6.6M.
The largest open-market purchase was 350,000 shares of ORIC at an average $4.92 on March 25, 2022, about $1.7M. Twelve months later ORIC was up 16%.
The largest open-market sale was 125,000 shares of ORIC at an average $10.80 on September 22, 2025, about $1.3M. Twelve months later ORIC was up 25%.
4 of the 12 sales since April 2023 were made under a Rule 10b5-1 trading plan; the other 8 were not.
| Date | Ticker | Role | Type | Shares | Price | Value | Chg% | 3M | 12M | SEC |
|---|---|---|---|---|---|---|---|---|---|---|
| Dec 16, 2025 | ORIC Oric Pharmaceuticals, Inc. | President and CEO | Sale+OE | 33,374 | $9.06 | $302,368.44 | -5.4% | +34.0% | - | |
| Oct 6, 2025 | ORIC Oric Pharmaceuticals, Inc. | President and CEO | Sell10b5-1 | 37,461 | $12.32 | $461,519.52 | -6.6% | -43.4% | -16.9% | |
| Oct 1, 2025 | ORIC Oric Pharmaceuticals, Inc. | President and CEO | Sell10b5-1 | 87,539 | $12.04 | $1,053,554.73 | -13.3% | -31.0% | +6.9% | |
| Sep 22, 2025 | ORIC Oric Pharmaceuticals, Inc. | President and CEO | Sell10b5-1 | 125,000 | $10.80 | $1,349,937.50 | -16.0% | -22.4% | +24.8% | |
| Dec 16, 2024 | ORIC Oric Pharmaceuticals, Inc. | President and CEO | Sale+OE | 24,660 | $8.28 | $204,214.39 | -3.1% | -4.0% | +10.7% | |
| Mar 6, 2024 | ORIC Oric Pharmaceuticals, Inc. | President and CEO | Sell | 40,000 | $16.21 | $648,380.00 | -5.2% | -46.0% | -51.0% | |
| Feb 7, 2024 | ORIC Oric Pharmaceuticals, Inc. | President and CEO | Sell | 40,000 | $12.23 | $489,346.18 | -4.9% | -23.7% | -0.5% | |
| Dec 15, 2023 | ORIC Oric Pharmaceuticals, Inc. | President and CEO | Sale+OE | 14,539 | $8.58 | $124,812.95 | -1.8% | +61.3% | -8.5% | |
| Jul 11, 2023 | ORIC Oric Pharmaceuticals, Inc. | President and CEO | Sell | 15,664 | $8.01 | $125,499.35 | -2.0% | -22.2% | +17.7% | |
| Jul 5, 2023 | ORIC Oric Pharmaceuticals, Inc. | President and CEO | Sell | 4,336 | $8.01 | $34,710.55 | -0.5% | -28.6% | -1.8% |